EU Panel Recommends Jaypirca for All CLL Patients, Pending Commission Approval
LLY•The European Medicines Agency's CHMP recommended approval of Jaypirca for chronic lymphocytic leukemia patients regardless of prior BTK inhibitor therapy. The opinion, backed by Phase 3 BRUIN CLL-313 and CLL-314 data, now advances to European Commission review with a final decision due within two months.
1. CHMP Recommendation
The EMA's Committee for Medicinal Products for Human Use recommended approval of Jaypirca for adult CLL patients regardless of prior BTK inhibitor therapy, marking the first EU opinion to cover all therapy lines. The recommendation now proceeds to the European Commission, with a final decision due in one to two months.
2. Supporting Phase 3 Data
The CHMP opinion was backed by results from the BRUIN CLL-313 and CLL-314 trials, which respectively assessed Jaypirca in treatment-naïve patients and compared non-covalent versus covalent BTK inhibitors. Both trials demonstrated favorable efficacy and safety profiles, supporting broader use across CLL indications.
3. Market Implications
Following the opinion, Eli Lilly shares rose nearly 6%, reflecting investor optimism about expanded European uptake. If approved by the Commission, Jaypirca could address a wide CLL patient population and strengthen Lilly's oncology portfolio ahead of a pending US regulatory decision in H2 2026.
